This activity was originally presented at the 2022 Asembia Specialty Pharmacy Summit.
Program Description
IgA nephropathy is an autoimmune disease that often begins asymptomatically and damages glomeruli in the kidneys, reducing their ability to filter waste products from the blood. This often causes progression to advanced kidney disease requiring dialysis or transplantation. However, it has been found that patients who are diagnosed earlier in the disease process and receive effective treatment have better overall outcomes. Pharmacists are well positioned to ensure patients with IgA nephropathy have access to health care and can initiate appropriate treatment with pharmacotherapy and supportive care options using guideline recommendations. This activity will explore clinical data and indications of medications to treat IgA nephropathy, with a focus on recently approved products and potential therapies under investigation and their targeted pathways. The fundamental elements for managed care and specialty pharmacists to assist in the development of supportive care pathways for patients with IgA nephropathy to improve disease management will also be discussed.
Target audience: Managed care pharmacists, specialty pharmacists, and health system pharmacists
Type of activity: Application
Release date: August 18, 2022
Expiration date: October 18, 2022
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explain the pathology of IgA nephropathy.
- Identify standard and newly approved therapies in current evidence-based guidelines for IgA nephropathy
- Employ disease management protocols and care pathways that promote early diagnosis and treatment to delay or prevent disease progression
Neeta Bahal O’Mara, PharmD, BCPS
Clinical Pharmacist
Coldstream Consulting, LLC
Skillman, New Jersey
Catherine E. Cooke, PharmD, MS, BCPS, PAHM
Research Associate Professor
University of Maryland School of Pharmacy
Baltimore, Maryland
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-342-L01-P. The activity is available for CE credit through October 18, 2022.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Faculty
Neeta Bahal O’Mara, PharmD, BCPS, and Catherine E. Cooke, PharmD, MS, BCPS, PAHM, have no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Karleen Melody, PharmD; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with commercial interests to disclose.
An anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
The content of this activity may include information regarding the use of products that may be inconsistent with, or outside the approved labeling for, these products in the United States. Pharmacists should note that the use of these products outside current approved labeling is considered experimental and are advised to consult the prescribing information for these products.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms